Inhaler choice and inhalation technique: key factors for asthma control

Despite the availability of highly effective therapies and evidence-based guidelines, many patients with asthma continue to suffer symptoms and exacerbations, with considerable disruption to their daily life. This may reflect under-diagnosis and poor adherence to therapy, as well as incorrect use of inhalers. For good asthma control, it is essential to prescribe appropriate medication according to the severity of the patient’s disease, and to ensure correct use of inhalers to facilitate effective drug delivery as well as adherence to the prescribed treatment.

The drug treatment regimen for the vast majority of asthmatic patients is straightforward and is delivered as documented by national and international guidelines. The choice of drug delivery device is less clear. Asthma guidelines currently provide little practical guidance on selection of inhaler devices. Rather than being spoilt for choice, physicians are more frequently confused by the ever increasing number of drug/device combinations. Therefore, without a clear process to aid clinical decision-making, the choice of inhaler may be counterproductive and can result in very little improvement in asthma control.

Evidence from the literature demonstrates that when used correctly there is little difference in clinical efficacy between different device types. However, a large number of patients are unable to use their inhalers properly, with a consequent reduction in therapeutic benefit. It is evident that no single inhaler device can satisfy the needs of all; therefore it is important that the most suitable inhaler is chosen for each individual patient. The most effective inhaler for any given patient is the one that the patient can and will use effectively on a regular basis. Patient adherence to medical advice is an important factor because, even if a patient can use an inhaler, we cannot assume that it will be used as prescribed. Successful control of asthma relies heavily on patients’ adherence to their prescribed inhaled therapies; it has been estimated that adherence rates for inhaler use are between 20% and 73%, and a lack of adherence is associated with an increase in asthma-related adverse effects.

In this issue of the Primary Care Respiratory Journal, the excellent review by Chrystyn and Price addresses problems associated with the use of pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), and summarises the use of each device by pointing out the positive and negative aspects of each. They also indicate factors to consider when prescribing an inhalation device, and, finally, describe the advantages of the newer hydrofluoroalkane-driven pMDIs which deliver ultrafine particles (unlike traditional pMDIs). However, little recognition has been given to the substantial role of nurses and pharmacists in either selecting appropriate inhaler devices for patients or in teaching and assessing inhaler technique. Trained asthma nurses fulfil a central role in education and in teaching patients about inhaler devices and encouraging adherence. Furthermore, community-based pharmacists can play a huge role not only in demonstrating the correct use of each type of inhaler they dispense to a patient, but also in identifying poorly controlled asthma by scanning the use of, and dispensing patterns of, bronchodilators versus inhaled steroids. To facilitate educational programs the pharmaceutical industry should provide placebos for each type of inhaler it produces to every dispensing pharmacist and prescribing clinician, as well as to any member of the health care team, upon request, free of charge.

Chrystyn and Price stress the importance of regular patient education, but they do not address the need to update healthcare professionals’ skills, knowledge and competence...
regularly. Many health professionals are limited in their ability to use inhaler devices properly and as a result they are not best placed to teach patients. There is a need to ensure that they are competent themselves to teach others.

Until now, there has been little clear comprehensive guidance to assist clinicians in the process of inhaler selection for their patients. General principles of inhaler selection and use have been reviewed in detail with a list of eight points to consider. An algorithm incorporating the patient’s inspiratory flow and ability to coordinate pMDI actuation with inspiration has been also proposed. More recently, the Aerosol Drug Management Improvement Team (ADMIT), a consortium of European respiratory physicians with a common interest in promoting excellent delivery of inhaled drugs, proposed a practical algorithm to facilitate patients’ instruction on optimal inhaler use. At each consultation, the physician should establish the patient’s current level of asthma control: if the disease has been well controlled for ≥3 months, therapy should be stepped down gradually according to guidelines; conversely, if the patient is poorly controlled, adherence to medical advice and (most importantly) inhalation technique should be assessed. If the patient is unable to use a particular inhaler correctly despite repeated attempts after instruction, an alternative inhaler should be considered. In cases where ongoing uncontrolled asthma persists despite correct inhaler technique, asthma therapy should be stepped up according to guidelines. Although there is no evidence that patients’ compliance is improved by changing to a different inhaler, it is likely that this strategy will be cost effective since it could facilitate control of asthma without increasing drug dosage or adding other agents.

We now need effectiveness studies, especially in the real world, to see whether this approach is applicable to the treatment of asthma patients in the community. We believe that choosing a method of drug administration in patients with obstructive airways diseases is as critical as the choice of medication itself, and that in future the choice of a new compound will be secondary to the need to choose the appropriate inhaler device.

The ADMIT Working Group
ADMIT is a consortium of European respiratory clinicians with special expertise in inhalation therapy who review published evidence to examine ways of improving the treatment of obstructive pulmonary airway diseases in Europe. ADMIT is supported by an unrestricted educational grant from MEDA AB. Members of ADMIT receive a small honorarium from MEDA AB for attending meetings, and travel expenses are reimbursed. See the first ADMIT paper published in this journal for a full list of individual conflict of interest declarations.

Conflict of interest declaration
Mark L Levy is the Editor-in-Chief of the PCRJ, but was not involved in the editorial review of, nor the decision to publish, this article.

Available online at http://www.thepcrj.org

References